Sep 23, 2026, 13:44 by ASAM Weekly Editors

Buprenorphine discontinuation challenges with 1 in 3 prescriptions abandoned, fentanyl-stimulant co-use risks, opioid-sedative co-use patterns, oral nicotine pouch trends in adolescents, and FDA hearing on psychedelics.

Sep 18, 2026, 15:03 by Sarah Shelson

The Pennsylvania Society of Addiction Medicine endorsed legislation that would regulate kratom in the state.

Sep 17, 2026, 13:56 by Sarah Shelson

ASAM is urging CMS to support access to addiction care by increasing payment for key prevention and treatment services.

Sep 16, 2026, 11:40 by ASAM Weekly Editors

Stimulant-only overdose deaths rising amid opioid decline, care navigation for methamphetamine use disorder, cannabis detected in 21% of overdose deaths, prescription cannabis use disorder, adolescent polysubstance co-use and dosing, Addiction Consult Services reducing readmissions, prenatal alcohol exposure and brain maturation, and youth substance use ED visits.

Sep 16, 2026, 09:47 by Sarah Shelson

The American Society of Addiction Medicine (ASAM) has sent a letter to Congressional leaders urging them to pass the bipartisan Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0) before the end of the year.

Sep 9, 2026, 11:03 by ASAM Weekly Editors

Fatal overdose isolation patterns from SUDORS 2022–2024, police drug market disruptions and overdose risk in San Francisco, medetomidine emergence in Philadelphia, methadone versus buprenorphine survival after nonfatal overdose, expanding alcohol screening to reduce premature mortality, unauthorized e-cigarette market dominance, and ADAPT for adolescent SUD treatment.

Sep 2, 2026, 17:49 by ASAM Weekly Editors

E-cigarette cessation recommendations for US clinicians, early buprenorphine initiation and hospital discharge outcomes, vending machine naloxone access post-incarceration, global OUD treatment and harm reduction survey, nonmedical gabapentin use patterns, and Meta's $18 billion social media addiction settlement.

Sep 2, 2026, 13:46 by Sarah Shelson

ASAM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. The OPPS is the regulatory framework CMS uses to establish Medicare payment policies for services delivered in hospital outpatient departments.

Sep 1, 2026, 09:00 by Sarah Shelson

The American Society of Addiction Medicine (ASAM) has received a three-year cooperative agreement from the Substance Abuse and Mental Health Services Administration (SAMHSA) to lead the Providers Clinical Support System – Substance Use Disorder Treatment (PCSS-SUD Treatment) program.

Aug 26, 2026, 10:37 by ASAM Weekly Editors

Guest editorial on healing and connection in addiction medicine, plus semaglutide for AUD, HRV biosignatures for craving, THC and airway dysfunction, self-management programs for SUD, and nicotine vaping trends.

Aug 25, 2026, 13:21 by R. Corey Waller, MD, MS, FACEP, DFASAM

Dr. Jessica Gregg, FASAM, on the tension between patient volume and meaningful connection in addiction medicine, and why true healing requires communion.

Aug 19, 2026, 15:17 by ASAM Weekly Editors

Virtual SUD clinic implementation insights, epigenetic aging and substance use, cannabis hyperemesis syndrome trends, the SCOPE OUD risk calculator, and gambling disorder in older adults.

Aug 12, 2026, 11:54 by ASAM Weekly Editors

Guest editorial on street addiction medicine for opioid and stimulant use disorder in unhoused populations, naltrexone and bupropion mediators, and pain management in OUD treatment.

Aug 12, 2026, 07:41 by Sarah Shelson

While payments for opioid treatment programs have been annually updated to help keep pace with rising practice costs, payments for services furnished by addiction-treatment clinicians outside of OTPs have not.

Aug 11, 2026, 10:52 by R. Corey Waller, MD, MS, FACEP, DFASAM

Dr. Katia Cnop of USC Street Medicine examines patient-centered approaches to opioid and stimulant use disorder care for people experiencing unsheltered homelessness, including direct-to-inject buprenorphine protocols, stimulant use disorder treatment, and the barriers that street medicine programs are working to overcome.

Aug 6, 2026, 11:52 by ASAM Weekly Editors

Is there anything better than a brand-new federal dataset? The Substance Abuse and Mental Health Services Administration (SAMHSA) recently released findings from the 2025 National Survey on Drug Use and Health (NSDUH) and they do not disappoint. From fresh figures for our slides to encouraging drops in conditions such as alcohol use disorder (AUD) rates, this report gives us the clearest snapshot yet of the post-pandemic behavioral health landscape.

Jul 31, 2026, 17:03 by Sarah Shelson

On July 30, 2026, ASAM submitted comments to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH).

Jul 30, 2026, 10:39 by ASAM Weekly Editors

Methamphetamine use disorder remains a significant public health issue with high rates of morbidity and mortality and the absence of any United States Food and Drug Administration (FDA)-approved treatments. Therefore, the original report from the NIDA Clinical Trials Network (CTN) ADAPT-2 trial was an important milestone, demonstrating that extended-release naltrexone plus bupropion outperformed placebo in adults with moderate to severe methamphetamine use disorder. Yet, overall improvement remained modest, with only 16.5% of participants meeting the initial treatment response threshold.

Jul 29, 2026, 17:52 by Sarah Shelson

Jul 28, 2026, 08:00 by R. Corey Waller, MD, MS, FACEP, DFASAM

Methamphetamine use disorder remains a significant public health issue with high rates of morbidity and mortality and the absence of any United States Food and Drug Administration (FDA)-approved treatments.